Restrictive Versus Liberal Transfusion in Patients with Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the Myocardial Ischemia and Transfusion (MINT) Trial

Andrew P DeFilippis,J Dawn Abbott,Brandon M Herbert,Marnie H Bertolet,Bernard R Chaitman,Harvey D White,Andrew M Goldsweig,Tamar S Polonsky,Rajesh Gupta,Caroline Alsweiler,Johanne Silvain,Pedro G M de Barros E Silva,Graham S Hillis,Benoit Daneault,Meechai Tessalee,Mark A Menegus,Sunil V Rao,Renato D Lopes,Paul C Hébert,John H Alexander,Maria M Brooks,Jeffrey L Carson,Shaun G Goodman,MINT Investigators
DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.071208
IF: 37.8
2024-08-29
Circulation
Abstract:Background: The MINT trial raised concern for harm from a restrictive versus liberal transfusion strategy in patients with acute myocardial infarction (MI) and anemia. Type 1 and type 2 MI are distinct pathophysiological entities that may respond differently to blood transfusion. This analysis sought to determine if the effects of transfusion varied among patients with a type 1 or a type 2 MI and anemia. We hypothesized that the liberal transfusion strategy would be of greater benefit in type 2 than in type 1 MI. Methods: We compared rates of death or MI at 30 days in patients with type 1 (n=1460) and type 2 (n=1955) MI and anemia who were randomly allocated to a restrictive (threshold of 7 to 8 g/dL) or a liberal (threshold of 10 g/dL) transfusion strategy. Results: The primary outcome of death or MI was observed in 16% of type 1 MI and 15.4% of type 2 MI patients. The rate of death or MI was higher in patients with type 1 MI randomized to a restrictive (18.2%) versus liberal (13.2%) transfusion strategy (RR 1.32, 95% CI 1.04 - 1.67) with no difference observed between the restrictive (15.8% ) and liberal (15.1% ) transfusion strategies in patients with type 2 MI (RR 1.05 95% CI 0.85-1.29). The test for a differential effect of transfusion strategy by MI type was not statistically significant (P-interaction = 0.16). Conclusions: The concern for harm with a restrictive transfusion strategy in patients with acute MI and anemia raised in the MINT primary outcome manuscript may be more apparent in patients with type 1 than type 2 MI. Clinical trial registration: ClinicalTrials.gov number, NCT02981407.
What problem does this paper attempt to address?